Regulation of adipogenic differentiation and adipose tissue inflammation by interferon regulatory factor 3.


Journal

Cell death and differentiation
ISSN: 1476-5403
Titre abrégé: Cell Death Differ
Pays: England
ID NLM: 9437445

Informations de publication

Date de publication:
11 2021
Historique:
received: 15 10 2020
accepted: 26 04 2021
revised: 21 04 2021
pubmed: 7 6 2021
medline: 24 3 2022
entrez: 6 6 2021
Statut: ppublish

Résumé

Dysfunction of adipocytes and adipose tissue is a primary defect in obesity and obesity-associated metabolic diseases. Interferon regulatory factor 3 (IRF3) has been implicated in adipogenesis. However, the role of IRF3 in obesity and obesity-associated disorders remains unclear. Here, we show that IRF3 expression in human adipose tissues is positively associated with insulin sensitivity and negatively associated with type 2 diabetes. In mouse pre-adipocytes, deficiency of IRF3 results in increased expression of PPARγ and PPARγ-mediated adipogenic genes, leading to increased adipogenesis and altered adipocyte functionality. The IRF3 knockout (KO) mice develop obesity, insulin resistance, glucose intolerance, and eventually type 2 diabetes with aging, which is associated with the development of white adipose tissue (WAT) inflammation. Increased macrophage accumulation with M1 phenotype which is due to the loss of IFNβ-mediated IL-10 expression is observed in WAT of the KO mice compared to that in wild-type mice. Bone-marrow reconstitution experiments demonstrate that the nonhematopoietic cells are the primary contributors to the development of obesity and both hematopoietic and nonhematopoietic cells contribute to the development of obesity-related complications in IRF3 KO mice. This study demonstrates that IRF3 regulates the biology of multiple cell types including adipocytes and macrophages to prevent the development of obesity and obesity-related complications and hence, could be a potential target for therapeutic interventions for the prevention and treatment of obesity-associated metabolic disorders.

Identifiants

pubmed: 34091599
doi: 10.1038/s41418-021-00798-9
pii: 10.1038/s41418-021-00798-9
pmc: PMC8563729
doi:

Substances chimiques

Interferon Regulatory Factor-3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3022-3035

Subventions

Organisme : Medical Research Council
ID : MC_UU_00014/2
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/12/13/29853
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/7/33636
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0802051
Pays : United Kingdom
Organisme : Medical Research Council
ID : MRC_MC_UU_12012/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400192
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_G0802535
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MRC_MC_UU_12012/2
Pays : United Kingdom

Informations de copyright

© 2021. The Author(s).

Références

Gesta S, Tseng YH, Kahn CR. Developmental origin of fat: tracking obesity to its source. Cell. 2007;131:242–56.
pubmed: 17956727 doi: 10.1016/j.cell.2007.10.004
Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab. 2009;20:16–24.
pubmed: 19008118 doi: 10.1016/j.tem.2008.09.002
Ali AT, Hochfeld WE, Myburgh R, Pepper MS. Adipocyte and adipogenesis. Eur J Cell Biol. 2013;92:229–36.
pubmed: 23876739 doi: 10.1016/j.ejcb.2013.06.001
Vazquez-Vela ME, Torres N, Tovar AR. White adipose tissue as endocrine organ and its role in obesity. Arch Med Res. 2008;39:715–28.
pubmed: 18996284 doi: 10.1016/j.arcmed.2008.09.005
Lefterova MI, Lazar MA. New developments in adipogenesis. Trends Endocrinol Metab. 2009;20:107–14.
pubmed: 19269847 doi: 10.1016/j.tem.2008.11.005
Farmer SR. Transcriptional control of adipocyte formation. Cell Metab. 2006;4:263–73.
pubmed: 17011499 pmcid: 1958996 doi: 10.1016/j.cmet.2006.07.001
Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, et al. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 2002;16:22–6.
pubmed: 11782441 pmcid: 155311 doi: 10.1101/gad.948702
Park KW, Halperin DS, Tontonoz P. Before they were fat: adipocyte progenitors. Cell Metab. 2008;8:454–7.
pubmed: 19041761 doi: 10.1016/j.cmet.2008.11.001
Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224–34.
pubmed: 7926726 doi: 10.1101/gad.8.10.1224
Wu Z, Puigserver P, Spiegelman BM. Transcriptional activation of adipogenesis. Curr Opin Cell Biol. 1999;11:689–94.
pubmed: 10600710 doi: 10.1016/S0955-0674(99)00037-X
White UA, Stephens JM. Transcriptional factors that promote formation of white adipose tissue. Mol Cell Endocrinol. 2010;318:10–4.
pubmed: 19733624 doi: 10.1016/j.mce.2009.08.023
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860–7.
pubmed: 17167474 doi: 10.1038/nature05485
Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–98.
pubmed: 20813258 pmcid: 2956412 doi: 10.1016/j.cell.2010.07.041
Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic disease. Nat Rev Immunol. 2011;11:738–49.
pubmed: 21984069 pmcid: 3383854 doi: 10.1038/nri3071
Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig. 2003;112:1796–808.
pubmed: 14679176 pmcid: 296995 doi: 10.1172/JCI200319246
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Investig. 2007;117:175–84.
pubmed: 17200717 pmcid: 1716210 doi: 10.1172/JCI29881
Xu J, Morinaga H, Oh D, Li P, Chen A, Talukdar S, et al. GPR105 ablation prevents inflammation and improves insulin sensitivity in mice with diet-induced obesity. J Immunol. 2012;189:1992–9.
pubmed: 22778393 doi: 10.4049/jimmunol.1103207
Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623–55.
pubmed: 11244049 doi: 10.1146/annurev.immunol.19.1.623
Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–84.
pubmed: 18303999 doi: 10.1146/annurev.immunol.26.021607.090400
Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, et al. Transcriptional control of adipose lipid handling by IRF4. Cell Metab. 2011;13:249–59.
pubmed: 21356515 pmcid: 3063358 doi: 10.1016/j.cmet.2011.02.005
Kong X, Banks A, Liu T, Kazak L, Rao RR, Cohen P, et al. IRF4 is a key thermogenic transcriptional partner of PGC-1α. Cell 2014;158:69–83.
pubmed: 24995979 pmcid: 4116691 doi: 10.1016/j.cell.2014.04.049
Eguchi J, Yan QW, Schones DE, Kamal M, Hsu CH, Zhang MQ, et al. Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab. 2008;7:86–94.
pubmed: 18177728 pmcid: 2278019 doi: 10.1016/j.cmet.2007.11.002
Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-α/β gene induction. Immunity 2000;13:539–48.
pubmed: 11070172 doi: 10.1016/S1074-7613(00)00053-4
Moreno-Navarrete JM, Petrov P, Serrano M, Ortega F, Garcia-Ruiz E, Oliver P, et al. Decreased RB1 mRNA, protein, and activity reflect obesity-induced altered adipogenic capacity in human adipose tissue. Diabetes 2013;62:1923–31.
pubmed: 23315497 pmcid: 3661645 doi: 10.2337/db12-0977
Furusyo N, Hayashi J. Glycated albumin and diabetes mellitus. Biochim Biophys Acta. 2013;1830:5509–14.
pubmed: 23673238 doi: 10.1016/j.bbagen.2013.05.010
Sartipy P, Loskutoff DJ. Expression profiling identifies genes that continue to respond to insulin in adipocytes made insulin-resistant by treatment with tumor necrosis factor-α. J Biol Chem. 2003;278:52298–306.
pubmed: 14530283 doi: 10.1074/jbc.M306922200
Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab. 2014;19:512–26.
pubmed: 24606904 pmcid: 4078000 doi: 10.1016/j.cmet.2014.01.018
Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med. 2006;12:549–56.
pubmed: 16617349 doi: 10.1038/nm1397
Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges. Brief Funct Genom. 2013;12:489–98.
doi: 10.1093/bfgp/elt028
Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996;87:377–89.
pubmed: 8898192 doi: 10.1016/S0092-8674(00)81359-8
Boden G. Obesity and free fatty acids. Endocrinol Metab Clin N Am. 2008;37:635–46, viii-ix.
doi: 10.1016/j.ecl.2008.06.007
Billiau A. Anti-inflammatory properties of Type I interferons. Antivir Res. 2006;71:108–16.
pubmed: 16626815 doi: 10.1016/j.antiviral.2006.03.006
Chang EY, Guo B, Doyle SE, Cheng G. Cutting edge: involvement of the type I IFN production and signaling pathway in lipopolysaccharide-induced IL-10 production. J Immunol. 2007;178:6705–9.
pubmed: 17513714 doi: 10.4049/jimmunol.178.11.6705
McNab FW, Ewbank J, Howes A, Moreira-Teixeira L, Martirosyan A, Ghilardi N, et al. Type I IFN induces IL-10 production in an IL-27-independent manner and blocks responsiveness to IFN-γ for production of IL-12 and bacterial killing in Mycobacterium tuberculosis-infected macrophages. J Immunol. 2014;193:3600–12.
pubmed: 25187652 pmcid: 4170673 doi: 10.4049/jimmunol.1401088
Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L, et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature. 2007;447:1116–20.
pubmed: 17515919 pmcid: 2587297 doi: 10.1038/nature05894
Zhao W, Wang L, Zhang M, Wang P, Zhang L, Yuan C, et al. Peroxisome proliferator-activated receptor γ negatively regulates IFN-β production in Toll-like receptor (TLR) 3- and TLR4-stimulated macrophages by preventing interferon regulatory factor 3 binding to the IFN-β promoter. J Biol Chem. 2011;286:5519–28.
pubmed: 21148557 doi: 10.1074/jbc.M110.149823
Weber KJ, Sauer M, He L, Tycksen E, Kalugotla G, Razani B, et al. PPARγ deficiency suppresses the release of IL-1β and IL-1α in macrophages via a type 1 IFN-dependent mechanism. J Immunol. 2018;201:2054–69.
pubmed: 30143592 doi: 10.4049/jimmunol.1800224
Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–20.
pubmed: 19633658 doi: 10.1038/nm.1964
Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15:930–9.
pubmed: 19633656 pmcid: 3115752 doi: 10.1038/nm.2002
Cipolletta D, Feuerer M, Li A, Kamei N, Lee J, Shoelson SE, et al. PPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012;486:549–53.
pubmed: 22722857 pmcid: 3387339 doi: 10.1038/nature11132
Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1304–10.
pubmed: 18420999 doi: 10.1161/ATVBAHA.108.165100
Rocha VZ, Folco EJ, Sukhova G, Shimizu K, Gotsman I, Vernon AH, et al. Interferon-γ, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res. 2008;103:467–76.
pubmed: 18658050 pmcid: 2740384 doi: 10.1161/CIRCRESAHA.108.177105
McLaughlin T, Liu LF, Lamendola C, Shen L, Morton J, Rivas H, et al. T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans. Arterioscler Thromb Vasc Biol. 2014;34:2637–43.
pubmed: 25341798 pmcid: 4445971 doi: 10.1161/ATVBAHA.114.304636
Pandolfi JB, Ferraro AA, Sananez I, Gancedo MC, Baz P, Billordo LA, et al. ATP-induced inflammation drives tissue-resident Th17 cells in metabolically unhealthy obesity. J Immunol. 2016;196:3287–96.
pubmed: 26951799 doi: 10.4049/jimmunol.1502506
Vega-Cardenas M, Uresti-Rivera EE, Cortes-Garcia JD, Briones-Espinoza M, Ruiz-Rodriguez VM, Reynaga-Hernandez E, et al. Increased levels of adipose tissue-resident Th17 cells in obesity associated with miR-326. Immunol Lett. 2019;211:60–7.
pubmed: 31136754 doi: 10.1016/j.imlet.2019.05.010
Guinn Z, Lampe AT, Brown DM, Petro TM. Significant role for IRF3 in both T cell and APC effector functions during T cell responses. Cell Immunol. 2016;310:141–9.
pubmed: 27641636 pmcid: 5125847 doi: 10.1016/j.cellimm.2016.08.015
Ysebrant de Lendonck L, Tonon S, Nguyen M, Vandevenne P, Welsby I, Martinet V, et al. Interferon regulatory factor 3 controls interleukin-17 expression in CD8 T lymphocytes. Proc Natl Acad Sci USA. 2013;110:E3189–97.
pubmed: 23918362 pmcid: 3752229 doi: 10.1073/pnas.1219221110
Morris DL, Cho KW, Delproposto JL, Oatmen KE, Geletka LM, Martinez-Santibanez G, et al. Adipose tissue macrophages function as antigen-presenting cells and regulate adipose tissue CD4+ T cells in mice. Diabetes 2013;62:2762–72.
pubmed: 23493569 pmcid: 3717880 doi: 10.2337/db12-1404

Auteurs

Peng Tang (P)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Sam Virtue (S)

Institute of Metabolic Science, Wellcome Trust-MRC MDU Metabolic Disease Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Jian Yi Gerald Goie (JYG)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Chin Wen Png (CW)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Jing Guo (J)

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Ying Li (Y)

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Huipeng Jiao (H)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Yen Leong Chua (YL)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Mark Campbell (M)

Institute of Metabolic Science, Wellcome Trust-MRC MDU Metabolic Disease Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

José Maria Moreno-Navarrete (JM)

Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigacio Biomedica de Girona (IDIBGI), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn, CB06/03/010), Instituto de Salud Carlos III, and Department of Medical Sciences, Faculty of Medicine, Girona, Spain.

Asim Shabbir (A)

Department of Surgery, National University Hospital, Singapore, Singapore.

José-Manuel Fernández-Real (JM)

Department of Diabetes, Endocrinology and Nutrition, Institut d'Investigacio Biomedica de Girona (IDIBGI), CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn, CB06/03/010), Instituto de Salud Carlos III, and Department of Medical Sciences, Faculty of Medicine, Girona, Spain.

Stephan Gasser (S)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

David Michael Kemeny (DM)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.

Henry Yang (H)

Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Antonio Vidal-Puig (A)

Institute of Metabolic Science, Wellcome Trust-MRC MDU Metabolic Disease Unit, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. ajv22@medschl.cam.ac.uk.

Yongliang Zhang (Y)

Department of Microbiology & Immunology, and NUSMED Immunology Translational Research Programme,Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. miczy@nus.edu.sg.
Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore. miczy@nus.edu.sg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH